This is a working overview of GHSR-1a, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-24 and is reviewed periodically as new material appears.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
冻干状态下的肽通常比溶液状态更稳定，常规做法是维持 -20 °C 或更低温度、保持干燥并避开强光。复溶后的降解主要来自水解、氧化与脱酰胺，速率受 pH、缓冲液种类、离子强度与温度共同影响，碱性条件一般会加快这些反应。反复冻融会造成聚集与容器吸附损失，分装保存能降低该风险。容器材质与金属离子也可能参与氧化过程，需与操作条件一并考虑。
对 ipamorelin 的常规表征以反相高效液相色谱测定纯度，检测波长多设为 214 nm，因为肽键在该波长有较强吸收。身份确认通常借助电喷雾电离质谱或串联质谱，将实测分子量与理论值逐项比对。序列层面可用肽图分析或氨基酸分析进一步验证。这些手段组合起来，可以分别覆盖纯度、身份与序列三个不同层次的信息。
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Value for the free base |
| Molar mass | 711.9 g/mol | Calculated from the formula |
| Appearance | White to off-white powder | Typical lyophilized form |
| Mechanism class | Ghrelin receptor agonist | Also described as a secretagogue |
| Half-life | About 2 hours | Reported for human circulation |
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
parish of Saint-Eustache, parish of Saint-Nicolas-du-Chardonnet, parish of Saint-Sauveur, parish of Saint-Jean-en-Grève, parish of Saint-André-des-Arcs, Saint-Sulpice parish (mortuaries), parish of Saint-Sulpice (baptisms), parishes of la Madeleine de la Ville-l'Évêque, Saint-Honoré, Saint-Landry, Saint-Médard, Saint-Merry, Saint-Roch.
== Biosynthesis == OPH is created using the precursor 2-aminobutyric acid through consecutive reactions of the same enzymes that create GSH, namely Glutamate–cysteine ligase and glutathione synthetase. Major regulators of OPH biosynthesis are local (relative) concentrations of cysteine and 2-aminobutyric acid, as well as their γ-glutamyl intermediate products.
Hypnotica was a class of somniferous drugs and substances tested in medicine of the 1890s and later. These include urethan, acetal, methylal, sulfonal, paraldehyde, amylenhydrate, hypnon, chloralurethan, ohloralamid, or chloralimid. Research about using medications to treat insomnia evolved throughout the last half of the 20th century. Treatment for insomnia in psychiatry dates back to 1869, when chloral hydrate was first used as a soporific. Barbiturates emerged as the first class of drugs in the early 1900s, after which chemical substitution allowed derivative compounds. Although they were the best drug family at the time (with less toxicity and fewer side effects), they were dangerous in overdose and tended to cause physical and psychological dependence. During the 1970s, quinazolinones and benzodiazepines were introduced as safer alternatives to replace barbiturates; by the late 1970s, benzodiazepines emerged as the safer drug. Benzodiazepines are not without their drawbacks; substance dependence is possible, and deaths from overdoses sometimes occur, especially in combination with alcohol or other depressants. Questions have been raised as to whether they disturb sleep architecture. Nonbenzodiazepines or Z-drugs like zolpidem were introduced in the 1980s and 1990s. Although it is clear that they are less toxic than barbiturates, their predecessors, comparative efficacy over benzodiazepines has not been established. Such efficacy is hard to determine without longitudinal studies.
Each module performs all the catalytic reactions necessary to incorporate a single amino acid onto the peptide chain. This is accomplished through the subdomains for adenylation (A), peptityl carrier protein (PCP), condensation (C), and depending on the amino acid position, an epimerization (E). The adenylation subdomain is used in activating the specific amino acid. Each module uses one molecule of the selected substrate amino acid with one molecule of ATP to give an aminoacyl adenylate enzyme complex and pyrophosphate. The activated amino acid can then be transferred to the enzyme bound 4'-phosphopantetheine of the carrier protein with the expulsion of AMP from the system. The carrier protein uses the 4'-phosphopantetheine prosthetic group for loading of the growing peptide and their monomer precursors. Elongation of the peptide chain is achieved through condensation of the upstream PCP onto an adjacent downstream PCP-bound monomer. Some domains have modification subdomains, such as the E subdomain seen in domains 1 and 4 in tyrocidine, which will generate the D-configured amino acid. On the final module is the TE domain used as a catalyst for cyclization or product release. The release of the product from the carrier protein is achieved through acylation of the active site serine of TE in which the decapeptide is transferred from the thiol ether to the serine residue. Deacylation can then occur through intramolecular cyclization or through hydrolysis to give the cyclic or linear product respectively (See figure 4).
=== Pharmacokinetics === Suvomipic is used topically on the scalp instead of orally for potential safety and tolerability reasons. As an example, MPCs and pyruvate availability also prominently regulate stem cells and cellular growth in the intestines. The drug is said to be unstable in blood, which limits the risk of systemic absorption and side effects. It is said to have been engineered to be 1,000 times more effective at "penetrating" skin than blood. No suvomipic was detected in circulation with topical administration to the scalp in clinical studies.
Sources: en.wikipedia.org
Fabomotizole (INN), sold under the brand name Afobazole, is an anxiolytic drug launched in Russia in the early 2000s. It produces anxiolytic and neuroprotective effects without any sedative or muscle relaxant actions. Its mechanism of action remains poorly defined however, with GABAergic, NGF- and BDNF-release-promoting, MT1 receptor agonism, MT3 receptor antagonism, and sigma agonism suggested as potential mechanisms. Fabomotizole was shown to inhibit MAO-A reversibly and may potentially have some involvement with serotonin receptors. Clinical trials have shown fabomotizole to be well tolerated and reasonably effective for the treatment of anxiety. Experiments in mice have shown antimutagenic and antiteratogenic properties. Experiments in rats have shown beneficial effect in the model of ischemic stroke. Fabomotizole has found little clinical use outside Russia and has not been evaluated by the FDA.
=== Risk to the social safety net === CBO estimates OBBBA would cause 10.9 million Americans to lose health insurance coverage. Other estimates of this figure said it would strip nearly nine million people of their coverage, leaving between 10.3 million to 14 million people uninsured. The bill's cuts to Medicaid were the largest in the program's history and put rural hospitals at risk of closure with one clinic attributing their announced closure to the bill. The loss of coverage for millions of Americans is expected to strain the finances of hospitals, nursing homes, and community health centers, which will be left to absorb more of the cost of treating the uninsured. Further CBO analysis released August 11, 2025, estimated that the highest 10% of earners would see incomes rise by 2.7% by 2034 mainly due to tax cuts, while the lowest 10% would see incomes fall by 3.1% mainly due to cuts to programs such as Medicaid and food aid. Analysis of the bill by the CBO and multiple think tanks found it to be one of the most regressive bills in decades. The Center for a Responsible Federal Budget estimates that the bill will accelerate the estimated insolvency of Social Security and Medicare by one year. Experts have argued that the bill would create the largest upward transfer of wealth from the poor to the rich in American history due to large-scale benefit cuts paired with tax breaks for high-income earners and corporations.
The canal remained a remote and sparsely populated wilderness, unchanged over centuries. The Upper Orinoco, at its junction with the Casiquiare, was over a thousand miles from the sea and still more than a quarter mile wide. The expedition proceeded to Esmeralda, a remote mission at the foot of the Sierra Duida. The settlement was isolated and regarded as a place of hardship, plagued by insects and food shortages. Esmeralda was famous for the production of curare, a potent poison prepared by local Natives. Humboldt and Bonpland observed its preparation and collected samples, narrowly avoiding accidental poisoning. Hostile indigenous groups upriver from Esmeralda forced the party to abandon plans to explore the Orinoco’s source. Weakened by insects, poor food, and cramped conditions, the expedition left Esmeralda on 23 May. They traveled rapidly downstream, reaching the Atures rapids by the end of May. Humboldt visited the cavern of Ataruipe, discovering hundreds of well-preserved Native skeletons. He collected several for scientific study, which later caused difficulties with locals who recognized the resin used in their preparation. The expedition passed through the rapids for the last time. Father Zea left to rejoin his mission. Many of the local Natives suffered from illness. Bonpland soon fell sick but continued to collect plants despite worsening health. In early June, the group reached Uruana and encountered the Ottomac people. Humboldt described them as unruly, hard to govern, and addicted to a hallucinogenic drug.
Andrea Patricia Clausen (born 1971) is a British civil servant in the Falkland Islands who has been the Chief Executive of the Falkland Islands since 2025. She is the first resident of the Falkland Islands and first woman to serve as chief executive. Prior to her tenure as chief executive she was a member of the Legislative Assembly of the Falkland Islands from 2005 to 2009.
Furthermore, synthetic platelet-based drug carriers can be loaded with radiosensitizers, which also improve the effectiveness of radiation therapy by increasing tumor susceptibility to radiation-induced damage. Another advantage of platelet-based treatments is their potential to overcome drug resistance—a danger of current cancer treatment options. By acting as sentinels in the bloodstream, platelets naturally take up proteins and genetic material. New treatments can leverage this for real-time biomarker detection and therapeutic monitoring. This application provides the basis for the development of liquid biopsies based on platelets to track disease progression and treatment efficacy. One of the largest constraints is the challenge of mimicking natural platelet interactions with cancer cells without accidentally stimulating cancer growth or metastasis. Natural platelets play a dual role in cancer progression in that they can help the immune system fight tumors but also facilitate cancer cell survival and metastasis by shielding circulating tumor cells from immune attack. Synthetic platelets must be carefully engineered to retain their therapeutic benefits while avoiding unintended interactions that could enhance tumor growth. Additionally, the stability, circulation time, and biodegradability of the synthetic platelets must be optimized for long-term therapeutic action without triggering unwanted immune responses.
Sources: en.wikipedia.org
A similar stele fragment (ES 1027), 57 centimeters high by 42 centimeters wide by 20 deep, depicting Naram-Sin was found a few miles north-east of Diarbekr, at Pir Hüseyin in a well, though this was not its original context. It is said to have been first found in Miyafarkin, a village about 75 kilometers northeast of Diarbekr. Fragments of an alabaster stele representing captives being led by Akkadian soldiers is sometimes attributed to Narim-Sin (or Rimush or Manishtushu) on stylistic grounds. In particular, it is considered as more sophisticated graphically than the steles of Sargon of Akkad or those of Rimush or Manishtushu. Two fragments (IM 55639 and IM 59205) are in the National Museum of Iraq, and one (MFA 66.89) is the Boston Museum. The stele is quite fragmentary, but attempts at reconstitution have been made. Depending on sources, the fragments were excavated in Wasit, al-Hay district, Wasit Governorate, or in Nasiriyah, both locations in Iraq. It is thought that the stele represents the result of the campaigns of Naram-Sin to Cilicia or Anatolia. This is suggested by the characteristics of the booty carried by the soldiers in the stele, especially the metal vessel carried by the main soldier, the design of which is unknown in Mesopotamia, but on the contrary well known in contemporary Anatolia.
=== Other dextran hydrogel targeted sites === Dextran conjugate hydrogels can also target other desirable sites. Paclitaxel-loaded dextran-sericin hydrogels can effectively target tumor growth in mice. Hydrogels composed of translocator protein (TSPO) ligands conjugated to dextran have the potential to induce apoptosis in tumor cells via the TSPO receptor on the mitochondria. Dextran/polyacrylamide hydrogels with covalently bound silver nanoparticles can effectively release ornidazole to treat infections. Dextran conjugated with oligolactide chains through a disulfide bond can form hydrogels that have potential applications in cancer treatment drug delivery systems. Dextran hydrogels that release drugs in response to an external electrical field can also be synthesized.
Between 12 and 14 June, Datafolha interviewed another 2,010 people in 112 Brazilian municipalities, and the Lula government received a good or excellent rating from 37% of respondents, regular from 33%, and bad or terrible from 27%. Three percent of respondents did not express an opinion. According to the survey, Lula's third term maintained a good "balance" of approval and regular ratings over five months, surpassing the ratings of the previous governments of Collor, Temer and Bolsonaro, but still being surpassed by the ratings of the first-term governments of FHC and Dilma. Between 15 and 18 June, the Genial/Quaest institute interviewed 2,029 voters over the age of 16, and the survey showed an increase in the rating from 51% to 56% again compared with the survey released in April of that year. That percentage represents those who said that Lula governs the country well, and the decrease from 42% to 40% represents those who said that Lula governs the country badly. From the end of June to the beginning of July, Lula's third government was measured by the newspaper PoderData, with 2,500 respondents from 262 municipalities across the country, ending the first half of the year with a "balance" in approval. Fifty-one percent of respondents rated Lula's administration positively, while 43% disapproved of the administration and 6% did not know how to rate it. The newspaper also asked respondents how they rated Lula governing the country, and in 3 months the percentage for good governance rose by two points (from 39% to 41%).
The earlier DOx drugs like DOM and DOET were subsequently followed by DOB, which was developed by Shulgin and colleagues like Claudio Naranjo, in 1971, and by DOI, DOC, and a few other analogues, which were developed by another research group, in 1973. After this, numerous other DOx drugs were synthesized and characterized, both by Shulgin and other scientists. Following its discovery, DOI has become widely used in scientific research in the study of the serotonin 5-HT2 receptors.
Sources: en.wikipedia.org
It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.
It binds the ghrelin receptor, known as the growth hormone secretagogue receptor type 1a. Activation of that receptor triggers signaling that leads to growth hormone release. Selectivity for growth hormone over cortisol and prolactin is the property most often cited for this compound.
Published estimates place the circulating half-life at roughly two hours in humans. Clearance involves peptidase activity and renal handling. Because the peptide is short-lived, release patterns after administration are usually described as pulsatile rather than sustained.
肽键在 214 nm 附近有较强吸收，适合检测缺少芳香侧链的短肽。该波长的基线受流动相组成与梯度影响较大。因此流动相与梯度条件需要固定并完整记录。